MAPT and Alzheimer disease: Validated biochemical biomarkers of AD are low concentrations of Aβ42 in cerebrospinal fluid (CSF), which reflect Aβ deposition in the brain, and increased tau in CSF, which is a marker of neuronal degeneration or damage.